Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss
NCT02997189
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
12
Enrollment
INDUSTRY
Sponsor class
Stopped
Negative Efficacy Results from the recently completed Phase 3 study 104-201506
Conditions
Cisplatin Induced Hearing Loss
Interventions
DRUG:
OTO-104
Sponsor
Otonomy, Inc.